Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Conduit Pharmaceuticals Inc. (CDTTW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/12/2025: CDTTW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -64.29% | Avg. Invested days 6 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/12/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2 | 52 Weeks Range 0.01 - 0.05 | Updated Date 05/21/2025 |
52 Weeks Range 0.01 - 0.05 | Updated Date 05/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -168.26% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 552357 |
Shares Outstanding - | Shares Floating 552357 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Conduit Pharmaceuticals Inc.
Company Overview
History and Background
Conduit Pharmaceuticals Inc. was formed to identify, acquire, develop, and commercialize late-stage drug candidates. The company aims to accelerate the development and approval of innovative therapies for unmet medical needs.
Core Business Areas
- Drug Development: Focuses on the clinical development and regulatory approval of acquired drug candidates.
- Commercialization: Involves the marketing and sale of approved pharmaceutical products.
- Acquisition and Licensing: Identifies and secures rights to promising late-stage drug candidates through acquisitions or licensing agreements.
Leadership and Structure
Details about the leadership team and organizational structure are not readily available in public sources.
Top Products and Market Share
Key Offerings
- AZD1656 (Bemcentinib): This is one of Conduit's lead assets and is an investigational oral selective inhibitor of tyrosine kinase Tyro3, Axl, and Mer (TAM). Details regarding its market share and competition are not available.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, high regulatory hurdles, and significant investment in research and development.
Positioning
Conduit Pharmaceuticals Inc. aims to differentiate itself by focusing on late-stage drug candidates, potentially reducing development risk and accelerating time to market.
Total Addressable Market (TAM)
The specific TAM depends on the therapeutic areas targeted by Conduit's drug candidates and is not precisely defined in publicly available information. However, the broader pharmaceutical market is valued in the hundreds of billions of dollars annually.
Upturn SWOT Analysis
Strengths
- Focus on late-stage assets
- Experienced management team (if available)
- Potential for accelerated development timelines
Weaknesses
- Dependence on successful acquisition and development of assets
- High regulatory risk
- Limited commercial infrastructure
Opportunities
- Acquire promising drug candidates at favorable terms
- Partner with larger pharmaceutical companies for commercialization
- Expand into new therapeutic areas
Threats
- Failure of clinical trials
- Regulatory setbacks
- Competition from established pharmaceutical companies
Competitors and Market Share
Key Competitors
- Big Pharma names like Pfizer (PFE), Novartis (NVS) or AstraZeneca (AZN) depending on the specific therapy areas they target. It also depends on who makes competing tyrosine kinase inhibitor drugs.
Competitive Landscape
Conduit Pharmaceuticals Inc. faces significant competition from established pharmaceutical companies with greater resources and expertise. The company's success depends on its ability to efficiently acquire, develop, and commercialize innovative therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is limited due to the company's recent formation.
Future Projections: Future growth projections depend on the successful development and commercialization of its drug candidates. Analyst estimates are not widely available.
Recent Initiatives: Recent strategic initiatives likely include the acquisition and advancement of drug candidates, securing financing, and building a team.
Summary
Conduit Pharmaceuticals Inc. is a pharmaceutical company focused on acquiring and developing late-stage drug candidates. Its success hinges on the successful clinical trials and regulatory approvals of its lead assets. Its focus on late-stage assets offers the potential for quicker market entry, but the company faces significant competition and regulatory hurdles. The company will need to strategically manage its pipeline and secure partnerships to maximize its growth potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Press Releases
- SEC Filings (where available)
- Third-party pharmaceutical industry reports
Disclaimers:
The information provided is based on publicly available sources and is not intended as investment advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Conduit Pharmaceuticals Inc.
Exchange NASDAQ | Headquaters Naples, FL, United States | ||
IPO Launch date 2023-09-25 | Founder, CEO & Director Dr. Andrew Regan | ||
Sector Healthcare | Industry Biotechnology | Full time employees 6 | Website https://www.conduitpharma.com |
Full time employees 6 | Website https://www.conduitpharma.com | ||
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products. The company was founded in 2019 and is based in Naples, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.